Integra LifeSciences
IART
223 hedge funds and large institutions have $3.63B invested in Integra LifeSciences in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 96 increasing their positions, 73 reducing their positions, and 38 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 73
26% more capital invested
Capital invested by funds: $2.88B → $3.63B (+$749M)
2.97% less ownership
Funds ownership: 91.27% → 88.3% (-3%)
6% less funds holding
Funds holding: 236 → 223 (-13)
26% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 38
Top Buyers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$129M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$98.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.4M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$22.1M |
| 5 |
O
OrbiMed
New York
|
+$20.4M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$59.3M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$53.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$22.7M |
| 4 |
IAM
Impax Asset Management
Portsmouth,
New Hampshire
|
-$17.7M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$13.1M |
IART Hedge Fund Activity: Q2 2017 in Review
223 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2017, worth a combined $3.63B — up 26% from $2.88B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of IART and 28 opened new positions — a net loss of 10 holders — while 73 trimmed existing stakes and 96 added.
The largest buyer was Capital Research Global Investors, adding an estimated $129M. The largest seller was Millennium Management, exiting entirely with an estimated $59.3M sold.
- 223 institutional investors held Integra LifeSciences (IART) as of Q2 2017, down from 236 in Q1 2017.
- Funds reported $3.63B of Integra LifeSciences stock for Q2 2017, up 26% quarter-over-quarter.
- 28 funds opened new Integra LifeSciences positions in Q2 2017 and 38 closed out, a net change of -10 holders.
- The largest Integra LifeSciences buyer in Q2 2017 was Capital Research Global Investors, an estimated $129M added.
- The largest Integra LifeSciences seller in Q2 2017 was Millennium Management, an estimated $59.3M sold.
Based on aggregated 13F filings for Q2 2017.